Tessa Timmers

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results

BackgroundWe aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria.MethodsThe SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission tomography scan, with annual follow-up. The primary outcome measure is clinical progression.ResultsCross-sectional evaluation of the first 151 participants (age 64 ± 8, 44% female, Mini-Mental State Examination 29 ± 2) showed that 28 (25%) had preclinical Alzheimer’s disease (AD) (amyloid status available n = 114 (75%)), 58 (38%) had subthreshold psychiatry, and 65 (43%) had neither. More severe subjective complaints were associated with worse objective performance. The SCD-plus criteria age ≥ 60 (OR 7.7 (95% CI 1.7–38.9)) and apolipoprotein E (genotype) e4 (OR 4.8 (95% CI 1.6–15.0)) were associated with preclinical AD.ConclusionsThe SCIENCe study confirms that SCD is a heterogeneous group, with preclinical AD and subthreshold psychiatric features. We found a number of SCD-plus criteria to be associated with preclinical AD. Further inclusion and follow-up will address important questions related to SCD.

Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron Emission Tomography

Alzheimers disease is a neurodegenerative condition that is neuropathologically characterized by the presence of amyloid-β plaques and neurofibrillary tangles consisting of tau. Recently, several positron emission tomography (PET) tracers have been developed that yielded promising initial results. In this chapter, we discuss how tau PET can be used in the context in clinical trials. We argue that simplified reference tissue models based on dynamic data acquisition are most suitable for accurately measuring changes in tau pathology in trials tailored to reduce cerebral tau load. Therefore, we discuss the importance of tracer kinetic modeling and describe in detail how a reliable measurement of specific binding can be obtained.

[18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER’S DISEASE SPECTRUM

P2-359 RELATION NETWORKS OF NEURODEGENERATION INALZHEIMER’S DISEASE SPECTRUM: TAU, AMYLOID, AND CORTICAL ATROPHY Jeong-Hyeon Shin, Sang Won Seo, Jee Hoon Roh, Minyoung Oh, Jungsu S. S. Oh, Seung Jun Oh, Jae Seung Kim, Joon-Kyung Seong, Korea University, Seoul, South Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Contact e-mail: sjhtom@naver.com

AMYLOID-β LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE

O2-06-03 AMYLOID-b LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE Sander C. J. Verfaillie, Tessa Timmers, Rosalinde E. R. Slot, Chris W. J. van der Weijden, Linda M. P. Wesselman, Niels D. Prins, Sietske A. M. Sikkes, Adriaan A. Lammertsma, Philip Scheltens, Rik Ossenkoppele, Bart N. M. van Berckel, Wiesje M. Van der Flier, VU University Medical Center, Amsterdam, Netherlands; Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, Netherlands; Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, Netherlands; Harvard Medical School, Boston University, Boston, MA, USA; Neuroscience Campus Amsterdam, Amsterdam, Netherlands; VU University Medical Center, Amsterdam Neuroscience, Amsterdam, Netherlands; Lund University, Lund, Sweden; Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, Netherlands. Contact e-mail: s.verfaillie@vumc.nl

PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER’S PATIENTS AND CONTROLS USING FLORTAUCIPIR

P4-235 PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER’S PATIENTS ANDCONTROLS USING FLORTAUCIPIR Emma E. Wolters, Sandeep S. V. Golla, Tessa Timmers, Rik Ossenkoppele, Colin Groot, Chris W. J. van der Weijden, Sander C. J. Verfaillie, Philip Scheltens, Wiesje M. van der Flier, Lothar A. Schwarte, Mark A. Mintun, Michael D. Devous, Sr., Robert C. Schuit, Albert D. Windhorst, Adriaan A. Lammertsma, Ronald Boellaard, Bart N. M. van Berckel, Maqsood M. Yaqub, Department of Radiology & Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, Netherlands; Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, Netherlands; Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, Netherlands; Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, Netherlands; Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, Netherlands; Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, Netherlands; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands; Department of Anesthesiology, VU University Medical Center, Amsterdam, Netherlands; Avid Radiopharmaceuticals, Philadelphia, PA, USA; University Medical Center Groningen, Groningen, Netherlands. Contact e-mail: ee.wolters@vumc.nl

Lumbar puncture in patients with neurologic conditions

A lumbar puncture (LP) is performed to obtain cerebrospinal fluid. It is implemented in the clinic on a routine basis to aid the diagnosis of neurologic diseases. This paper accompanies an informative lumbar puncture video that shows the lumbar puncture procedure as routinely performed in the VUmc Alzheimer center based on the consensus guidelines by Engelborghs et al.

403 Validation of Bioelectrical Impedance Analysis with a Three-Component Model of Body Composition in 4-7 Year Old Children

403 Validation of Bioelectrical Impedance Analysis with a Three-Component Model of Body Composition in 4-7 Year Old Children

1096 Estimation of Body Composition in Children Aged 4-7: Body Mass Index, Skinfolds and Waist-To-Height Ratio Compared to Three Component Model

1096 Estimation of Body Composition in Children Aged 4-7: Body Mass Index, Skinfolds and Waist-To-Height Ratio Compared to Three Component Model